New Analysis Examines Financial Impact of Genotyping Patients to Guide Anti-Platelet Therapy | GenomeWeb

NEW YORK (GenomeWeb) – A group of researchers led by Samuel Johnson of Kaiser Permanente Colorado is hoping to garner the attention of payors and health systems by showing how CYP2C19 genotyping can help them differentiate which acute coronary syndrome patients would fare best on low-cost generic clopidogrel, and which would be better off on higher priced branded agents, Daiichi Sankyo/Eli Lilly's Effient (prasugrel) and AstraZeneca's Brilinta (ticagrelor).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.